AlloVir Enters Merger with Kalaris to Revolutionize Retinal Disease Treatments
Deal News | Nov 11, 2024 | EIN
AlloVir has entered into a definitive merger agreement with Kalaris Therapeutics to acquire all outstanding shares and create a new entity focused on retinal disease therapies. This all-stock transaction will see AlloVir shareholders owning 25.05% and Kalaris shareholders 74.95% of the merged company. Both companies' boards have approved the transaction, expected to close in Q1 2025, pending necessary approvals. The new entity, retaining the name Kalaris Therapeutics, will hold $100 million in cash reserves to support operations until Q4 2026. Kalaris CEO Andrew Oxtoby will lead the company, accompanied by COO Jeffrey Nau and medical lead Matthew Feinsod. Kalaris brings its innovative TH103 asset, under Phase I clinical trials for neovascular age-related macular degeneration, with plans for further evaluations. This merger combines AlloVir's financial muscle with Kalaris' clinical prowess, aiming to advance TH103's development, potentially impacting other retinal diseases like diabetic macular oedema and retinal vein occlusion.
Sectors
- Biotechnology
- Pharmaceuticals
Geography
- United States – Both AlloVir and Kalaris Therapeutics are based in the United States, where their operations and subsequent merger activities are taking place.
Industry
- Biotechnology – The merger focuses on developing therapies for retinal diseases, a central concern of the Biotechnology industry which involves the use of living organisms or their products for medical purposes.
- Pharmaceuticals – The article discusses the clinical development of retinal therapy TH103, aligning with the Pharmaceuticals industry's role in discovering, developing, and manufacturing drugs for therapeutic use.
Financials
- $100 million – Cash reserves of the combined entity post-merger to support operations and capital expenditures until Q4 2026.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| AlloVir | Buyer | Company | A biotechnology company focused on pioneering therapies for viral diseases, now merging with Kalaris Therapeutics. |
| Kalaris Therapeutics | Target Company | Company | A clinical-stage pharmaceutical company specializing in retinal disease therapies, merging with AlloVir. |
| Andrew Oxtoby | CEO of the combined company | Person | The current CEO of Kalaris Therapeutics who will lead the merged entity. |
| Jeffrey Nau | COO | Person | The Chief Operating Officer of the newly merged company. |
| Matthew Feinsod | Medical Lead | Person | Will serve as the medical lead for the combined company. |
| Diana Brainard | CEO of AlloVir | Person | The CEO of AlloVir, who announced the strategic merger. |
| David Hallal | Chair of the Board of AlloVir | Person | Chair of AlloVir's board who expressed support for the merger. |